1. Pink Sheet
  2. >>Market Access
  3. >>Pricing Debate

340B Provider Reforms Gaining Momentum In Congress

 
• By Cathy Kelly

House Energy & Commerce Committee recommends more oversight of hospital participation in the 340B drug discount program.

Syringes stuck in a dartboard

Congressional reform of the 340B outpatient prescription drug discount program is gathering momentum with the release of a report by the House Energy & Commerce Committee Jan. 10.

The report, which caps a two-year investigation, makes a number of recommendations to address concerns that oversight of 340B by the HHS Health Resources and Services Administration (HRSA) has not been able to keep pace with the rapid growth of the program

“Congress did not clearly identify the intent of the program and did not identify clear parameters, leaving the statute silent on many important program requirements

More from Pricing Debate

Medicare Negotiation Does Not Violate Due Process, Appeals Court Rules, Other Suits At Risk

 
• By Cathy Kelly

Decision in AstraZeneca’s lawsuit against the Health and Human Services Department is a precedent-setting victory for the government and a blow to manufacturer efforts to block the price negotiation program.

Most Favored Nation Pricing Policy Floated In Medicaid, Coming Back To Medicare?

 
• By Cathy Kelly

President Trump's ongoing interest in the policy, which would ensure the US government pays no more for prescription drugs than the lowest price available in comparable countries, continues to gain attention.

Brazil’s Drug Pricing Shake Up Calls For More Robust Evidence From Companies

 
• By Francesca Bruce

Brazil’s drug pricing authorities are planning to introduce, among other things, a new drug category for biosimilars to ensure the pricing procedures for such medicines are reflected in the official pricing framework.

Brazil To Upgrade Pricing Framework To Keep Up With Market Developments

 
• By Francesca Bruce

Brazil plans to clarify its medicine pricing framework, for example by outlining the procedures for setting medicine prices and bring it up to date with recent developments in the sector.

More from Market Access